TSPAN32 and acute lymphoblastic leukemia: Ultimately, a deeper understanding of TSPAN32 regulation may uncover novel therapeutic opportunities to restore quiescence programs in malignant lymphoid cells, potentially improving outcomes for patients with T-ALL.